Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database

被引:25
作者
Chan, D. -C. [1 ,2 ,3 ]
Chang, C. H. -C. [4 ]
Lim, L. -C. [2 ,5 ]
Brnabic, A. J. M. [6 ]
Tsauo, J. -Y. [7 ]
Burge, R. [8 ]
Hsiao, F. -Y. [9 ]
Jin, L. [10 ]
Gurbuz, S. [11 ]
Yang, R. -S. [5 ]
机构
[1] Natl Taiwan Univ Hosp, Chu Tung Branch, Superintendent Off, Taipei, Hsinchu County, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Geriatr & Gerontol, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[4] Eli Lilly & Co, Taipei, Taiwan
[5] Natl Taiwan Univ Hosp, Dept Orthopaed, 7 Chung Shan S Rd, Taipei 100, Taiwan
[6] Eli Lilly Australia Pty Ltd, Real World Analyt, Sydney, NSW, Australia
[7] Natl Taiwan Univ, Sch & Grad Inst Phys Therapy, Taipei, Taiwan
[8] Eli Lilly & Co, Global Hlth Outcomes, Indianapolis, IN 46285 USA
[9] Natl Taiwan Univ, Grad Inst Clin Pharm, Coll Med, Taipei, Taiwan
[10] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[11] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
Bone; Fractures; Medication adherence; Osteoporosis; Outcome assessment; Taiwan; Teriparatide; HIP-FRACTURE; PARATHYROID-HORMONE; OSTEOPOROTIC FRACTURES; POSTMENOPAUSAL WOMEN; POOR COMPLIANCE; RISK; PROGRAM; IMPACT; CARE; BISPHOSPHONATES;
D O I
10.1007/s00198-016-3611-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Summary Medication persistence and adherence are critical for osteoporosis outcomes. Using the Taiwan National Health Insurance Research Database, we found that persistence and adherence to teriparatide were low in Taiwanese patients with osteoporosis and that greater persistence and adherence were associated with a lower incidence of hip and other nonvertebral fractures. Introduction The purpose of this study was to determine the persistence and adherence to teriparatide treatment in Taiwanese patients with osteoporosis, and to examine the association between persistence and adherence to teriparatide with fracture risks. Methods Medical and pharmacy claims for 4,692 patients with vertebral or hip fractures and teriparatide prescriptions between 2005 and 2008 were identified (Taiwan National Health Insurance Research Database). Persistence was the time from the start of treatment to the first 90-day gap between two teriparatide prescriptions. Adherence was the number of teriparatide pens (each pen is used over 1 month) prescribed over 24 months. Association of persistence and adherence to teriparatide with fracture incidence was assessed using adjusted Cox proportional hazards models. Results The proportion of patients persisting with teriparatide for >6 months and >12 months was 44.6 and 24.9 %, respectively. Over 24 months, 53.6 % of patients were adherent for >6 months and 33.9% were adherent for >12 months. Patients persisting for >12 months had a significantly lower incidence of hip (adjusted hazard ratio [HR], 0.61 [95 % confidence interval (CI), 0.40-0.93], P=0.0229) and nonvertebral fracture (HR, 0.79 [95 % CI, 0.63-0.99], P=0.0462) compared with those who persisted for <= 12 months. Patients adherent for >12 months had a lower incidence of hip (HR, 0.66 [95 % CI, 0.46-0.96], P=0.0286) and nonvertebral fracture (HR, 0.81 [95 % CI, 0.66-0.99], P=0.0377) compared with those adherent for <= 12 months. Conclusions Persistence and adherence to teriparatide over 24 months were low in Taiwanese patients with osteoporosis; greater adherence and persistence were associated with a lower incidence of nonvertebral fractures.
引用
收藏
页码:2855 / 2865
页数:11
相关论文
共 42 条
[1]   Loss of treatment benefit due to low compliance with bisphosphonate therapy [J].
Beest, F. J. A. Penning-van ;
Erkens, J. A. ;
Olson, M. ;
Herings, R. M. C. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (04) :511-517
[2]   Screening, diagnosis and treatment of osteoporosis: a brief review [J].
Bernabei, Roberto ;
Martone, Anna Maria ;
Ortolani, Elena ;
Landi, Francesco ;
Marzetti, Emanuele .
CLINICAL CASES IN MINERAL AND BONE METABOLISM, 2014, 11 (03) :201-207
[3]   One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis [J].
Black, DM ;
Bilezikian, JP ;
Ensrud, KE ;
Greenspan, SL ;
Palermo, L ;
Hue, T ;
Lang, TF ;
McGowan, JA ;
Rosen, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (06) :555-565
[4]   Management of osteoporosis in fracture liaison service associated with long-term adherence to treatment [J].
Boudou, L. ;
Gerbay, B. ;
Chopin, F. ;
Ollagnier, E. ;
Collet, P. ;
Thomas, T. .
OSTEOPOROSIS INTERNATIONAL, 2011, 22 (07) :2099-2106
[5]   Consequences of poor compliance with bisphosphonates [J].
Briesacher, Becky A. ;
Andrade, Susan E. ;
Yood, Robert A. ;
Kahler, Kristijan H. .
BONE, 2007, 41 (05) :882-887
[6]   Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience [J].
Briot, K. ;
Ravaud, P. ;
Dargent-Molina, P. ;
Zylberman, M. ;
Liu-Leage, S. ;
Roux, C. .
OSTEOPOROSIS INTERNATIONAL, 2009, 20 (04) :625-630
[7]   Secondary prevention of osteoporotic fractures-an "OPTIMAL" model of care from Singapore [J].
Chandran, M. ;
Tan, M. Z. W. ;
Cheen, M. ;
Tan, S. B. ;
Leong, M. ;
Lau, T. C. .
OSTEOPOROSIS INTERNATIONAL, 2013, 24 (11) :2809-2817
[8]   Increases in BMD correlate with improvements in bone microarchitecture with Teriparatide treatment in postmenopausal women with osteoporosis [J].
Chen, Peiqi ;
Miller, Paul D. ;
Recker, Robert ;
Resch, Heinrich ;
Rana, Asad ;
Pavo, Imre ;
Sipos, Adrien A. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (08) :1173-1180
[9]   High incidence rate of hip fracture in Taiwan: estimated from a nationwide health insurance database [J].
Chie, WC ;
Yang, RS ;
Liu, JP ;
Tsai, KS .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (12) :998-1002
[10]   Pelvic Fracture and Risk Factors for Mortality: A Population-Based Study in Taiwan [J].
Chien, Li-Chien ;
Cheng, Hon-Mei ;
Chen, Weng-Chau ;
Tsai, Ming-Che .
EUROPEAN JOURNAL OF TRAUMA AND EMERGENCY SURGERY, 2010, 36 (02) :131-137